Background: In patients with acute myocardial infarction, altered cardiac repolarisation has been linked to ventricular fibrillation and major adverse cardiac events. Treatment of sleep disordered breathing early after acute myocardial infarction may normalise the ventricular ectopic substrate. Therefore, the aim of this ancillary analysis was to assess the effect of adaptive servoventilation (ASV) on cardiac repolarisation. Methods: This analysis included 42 participants from the prospective multicentre randomised trial TEAM-ASV I. 22 were randomised to early treatment with ASV in addition to standard care, and 20 to standard care only. Cardiac repolarisation was assessed by means of T-peak-to-end- (TpTe c ) and QT c - intervals and TpTe/QT-ratios derived from 12-lead ECG before and 4 and 12 weeks after percutaneous coronary intervention. Results: The population was predominantly male (79%), obese (mean± sd body mass index 31±6 kg·m −2 ), had severe sleep disordered breathing with an apnoea–hypopnoea index of 34±18 events·h −1 and ASV was initiated within 2.6±1 days. After 4 weeks, QT c significantly decreased in the ASV group compared to the control group (−5.8% versus −1.2%, p=0.041). A similar trend was observed with respect to TpTe c (−18.0% versus −6.8%, p=0.119) and TpTe/QT (−17.6% versus −6.6%, p=0.252). After 12 weeks, the decrease in repolarisation times was similar between the groups. (QT c −7.6% versus −4.5%, p=0.400; TpTe c −19.3% versus −18.8%, p=0.400; TpTe/QT −9.7 versus −13.0, p=0.652). Conclusion: In patients with first acute myocardial infarction and sleep disordered breathing, early treatment with ASV reduced cardiac repolarisation after 4 weeks, but not after 12 weeks. Thus, ASV may contribute to preventing ventricular arrhythmias in the vulnerable early phase after acute myocardial infarction.
Background: The prospective multicenter study TEAM-ASV-I investigated the effect of early treatment with adaptive servo-ventilation (ASV) in addition to percutaneous coronary intervention (PCI) and optimal medical therapy in first acute myocardial infarction (AMI). The aim of this subanalysis was to assess the effect of ASV on cardiac repolarization as surrogate for malignant ventricular arrhythmias. Methods: This ancillary analysis included 42 participants from the TEAM-ASV study, 22 with and 20 without ASV. Cardiac repolarization was assessed by means of T-peak-to-end (TpTec) and QTc-intervals and TpTe/QT-ratios derived from 12-lead ECG before, 4 and 12 weeks after PCI. Results: The population was predominantly male (79%), overweight (BMI 31±6 kg/m²) and had severe sleep-disordered breathing (AHI 34±18/h). Baseline parameters did not differ between the ASV and the non-ASV group. ASV was initiated within 2.6±1 days after AMI. AHI was lower in the ASV than in the non-ASV group after 12 weeks (3±7/h vs. 26±21/h, p<0.001). From baseline to 4 weeks, QTc significantly decreased in the ASV compared to the non-ASV group (−5.8% vs. -1.2%, p=0.041). A similar trend was seen with respect to TpTec (−18.0% vs. -6.8%, p=0.119) and TpTe/QT (−17.6% vs. -6.6%, p=0.252). After 12 weeks, the decline of repolarization times was similar between the groups (QTc: -7.6% vs. -4.5%, p=0.400; TpTec: -19.3% vs. -18.8%, p=0.400; TpTe/QT: -9.7 vs. -13.0, p=0.652). Conclusion: In patients with first AMI and SDB, treatment with ASV reduced cardiac repolarization after 4 weeks, but not after 12 weeks. This may help to prevent ventricular arrhythmias in the vulnerable early phase after AMI.
(1) Background: Early treatment of sleep-disordered breathing (SDB) with adaptive servo-ventilation (ASV) after acute myocardial infarction (AMI) has been shown to improve myocardial salvage. This analysis evaluates nocturnal electrocardiogram (ECG) Holter data, derived from polygraphy in a randomised clinical trial (NCT02093377), to assess the occurrence of nocturnal cardiac arrhythmias in patients with SDB and to explore the effect of ASV therapy. (2) Methods: In the TEAM-ASV I trial, patients were stratified by the presence/absence of SDB, defined by an apnoea–hypopnoea index (AHI) ≥15 events/h assessed with polygraphy. Those with SDB were subsequently randomised to receive ASV in addition to standard AMI care. Guideline-conforming semi-automated ECG analysis of nocturnal cardiac arrhythmias was conducted via Holter–ECG software (custo diagnostic, version 5.4). (3) Results: Patients with SDB had an increased incidence of non-sustained ventricular tachycardia (NSVT) (SDB: n = 8 (16%) vs. no SDB: n = 1 (2%); p = 0.024) and premature atrial contractions (PAC) (SDB: 1.2/h [0.3, 3.4] vs. no SDB: 0.3/h [0.1, 1.2]; p = 0.017). In patients with SDB who were randomised to ASV treatment early after AMI, we found no reduction in cardiac arrhythmias when ASV was added to standard care. (4) Conclusions: After AMI, SDB was linked to increased NSVT and PAC. ASV treatment demonstrated neither a harmful nor a beneficial effect on the occurrence of nocturnal cardiac arrhythmias. Further trials are warranted to confirm these findings.